Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Get Free Report) SVP Larry Todd Edwards sold 3,725 shares of the stock in a transaction that occurred on Wednesday, October 2nd. The stock was sold at an average price of $10.01, for a total transaction of $37,287.25. Following the completion of the transaction, the senior vice president now owns 136,635 shares in the company, valued at $1,367,716.35. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
Arcutis Biotherapeutics Trading Down 0.5 %
NASDAQ ARQT traded down $0.05 during trading hours on Thursday, hitting $10.18. 2,270,262 shares of the company were exchanged, compared to its average volume of 3,440,625. The stock has a market cap of $1.18 billion, a PE ratio of -3.47 and a beta of 1.17. Arcutis Biotherapeutics, Inc. has a 52 week low of $1.76 and a 52 week high of $13.17. The stock has a 50-day moving average price of $9.81 and a 200 day moving average price of $9.49. The company has a quick ratio of 8.19, a current ratio of 8.46 and a debt-to-equity ratio of 1.09.
Arcutis Biotherapeutics (NASDAQ:ARQT – Get Free Report) last released its quarterly earnings results on Wednesday, August 14th. The company reported ($0.42) earnings per share for the quarter, beating the consensus estimate of ($0.48) by $0.06. The company had revenue of $30.86 million for the quarter, compared to analyst estimates of $31.00 million. Arcutis Biotherapeutics had a negative return on equity of 145.41% and a negative net margin of 150.51%. During the same quarter in the prior year, the firm posted ($1.16) EPS. Analysts forecast that Arcutis Biotherapeutics, Inc. will post -1.56 earnings per share for the current fiscal year.
Analysts Set New Price Targets
View Our Latest Analysis on Arcutis Biotherapeutics
Institutional Trading of Arcutis Biotherapeutics
Several institutional investors have recently added to or reduced their stakes in the company. Cantor Fitzgerald L. P. bought a new position in shares of Arcutis Biotherapeutics during the fourth quarter valued at approximately $33,000. CWM LLC grew its position in Arcutis Biotherapeutics by 6,740.0% in the 2nd quarter. CWM LLC now owns 4,104 shares of the company’s stock valued at $38,000 after acquiring an additional 4,044 shares during the last quarter. Ameritas Investment Partners Inc. increased its stake in Arcutis Biotherapeutics by 55.2% in the first quarter. Ameritas Investment Partners Inc. now owns 7,871 shares of the company’s stock worth $78,000 after purchasing an additional 2,800 shares during the period. Algert Global LLC purchased a new stake in Arcutis Biotherapeutics in the second quarter worth $97,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in shares of Arcutis Biotherapeutics during the second quarter worth $174,000.
About Arcutis Biotherapeutics
Arcutis Biotherapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis.
Featured Stories
- Five stocks we like better than Arcutis Biotherapeutics
- Trading Stocks: RSI and Why it’s Useful
- When Is the Best Time to Invest in Mutual Funds?
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Is NVIDIA Stock in a Correction or Consolidation?
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- 3 Oversold Stocks with Big RSI Rebound Potential
Receive News & Ratings for Arcutis Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcutis Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.